Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company is headquartered in Oxford, Oxfordshire and currently employs 483 full-time employees. The company went IPO on 2021-10-01. The firm combines precision design with integrated experimentation to invent and develop drugs. The company uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. The company uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. The company has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. The company combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The firm's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.

Industry: Biological Products, (No Diagnostic Substances) Peers: Bicycle Therapeutics PLC Centessa Pharmaceuticals PLC Compass Pathways PLC Immunocore Holdings PLC Myovant Sciences Ltd.